Top Markets
#1 Black Phoenix Black Phoenix +355.14%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +63.00%
#4 Akedo Akedo +56.95%
#5 OpenEden OpenEden +56.78%
#6 BasedHype BasedHype +26.75%
#7 Cryptopia Cryptopia +21.54%
#8 Avantis Avantis +19.80%
#9 Humanity Humanity +19.59%
#10 Ether.fi Ether.fi +16.79%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
BiVictriX Therapeutics Plc BiVictriX Therapeutics Plc

BiVictriX Therapeutics Plc

BVX
Rank in Stocks #40613
BiVictriX Therapeutics Plc is a United Kingdom-based biotechnology firm... BiVictriX Therapeutics Plc is a United Kingdom-based biotechnology firm dedicated to pioneering innovative treatments for cancer. The company's core technology involves its distinctive Bi-Cygni therapeutics, which are engineered to precisely identify and combat specific cancer types. Their foremost development program, BVX001, is currently being advanced to address acute myeloid leukaemia. Established in 2016 as BiVictriX Plc, the organization officially adopted its present name, BiVictriX Therapeutics Plc, in August 2021. Its corporate headquarters are located in Macclesfield, United Kingdom.
Share Price
$0.13607016
Last synced: 2024-09-10
Market Cap
$112.29K
Change (1 day)
22.46%
Change (1 year)
0.00%
Country
GB
Trade BiVictriX Therapeutics Plc (BVX)

Category

Healthcare
P/E ratio for BiVictriX Therapeutics Plc (BVX)
P/E ratio as of 2026 TTM: 0
According to BiVictriX Therapeutics Plc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for BiVictriX Therapeutics Plc from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.